Apr 4
|
Amylyx to pull ALS drug from market in rare move
|
Mar 27
|
European study finds popular ALS drug ineffective
|
Mar 14
|
3 Pharma Stocks to Sell in March Before They Crash & Burn
|
Mar 14
|
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
|
Mar 14
|
Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
|
Mar 13
|
Analysts on Wall Street Lower Ratings for These 10 Stocks
|
Mar 12
|
After surprise trial failure, ALS doctors brace for one less treatment option
|
Mar 11
|
Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%
|
Mar 11
|
Amylyx CEOs look for a path forward following major setback
|
Mar 10
|
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Analysts Are Reducing Their Forecasts For This Year
|
Mar 10
|
Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn.
|
Mar 8
|
Amylyx Stock Wipes Out Nearly All Of Its Value, Crashing 82%, After Pivotal ALS Drug Failure
|
Mar 8
|
Maker of much-debated ALS drug says it may stop selling it after study showed it didn't work
|
Mar 8
|
Amylyx’s ALS Drug Fails Trial, Raising Questions About Company’s Future
|
Mar 8
|
10 Biotech Stocks with Huge Potential
|
Mar 8
|
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
|
Mar 8
|
Amylyx ALS drug fails crucial study, putting company’s future in doubt
|
Jan 5
|
2 Biotech Stocks With Huge Catalysts in 2024
|
Dec 26
|
Is Amylyx (AMLX) Stock a Solid Choice Right Now?
|
Dec 22
|
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)
|